Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Net Margin (2016 - 2025)

Historic Net Margin for Ligand Pharmaceuticals (LGND) over the last 15 years, with Q3 2025 value amounting to 101.57%.

  • Ligand Pharmaceuticals' Net Margin changed N/A to 101.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.34%, marking a year-over-year change of. This contributed to the annual value of 2.41% for FY2024, which is 11400.0% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Net Margin stood at 101.57% for Q3 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Net Margin registered a high of 101.57% during Q3 2025, and its lowest value of 93.64% during Q1 2025.
  • Moreover, its 5-year median value for Net Margin was 7.25% (2021), whereas its average is 11.21%.
  • Data for Ligand Pharmaceuticals' Net Margin shows a peak YoY increase of 627700bps (in 2021) and a maximum YoY decrease of -605700bps (in 2021) over the last 5 years.
  • Over the past 5 years, Ligand Pharmaceuticals' Net Margin (Quarter) stood at 3.94% in 2021, then plummeted by -49bps to 5.86% in 2022, then surged by 35bps to 3.79% in 2023, then tumbled by -1818bps to 72.62% in 2024, then surged by 240bps to 101.57% in 2025.
  • Its Net Margin stands at 101.57% for Q3 2025, versus 10.18% for Q2 2025 and 93.64% for Q1 2025.